1. General Drug Profile
Active Pharmaceutical Ingredient (API): Alprazolam
Brand Name: Xanax (manufactured by Viatris / Pfizer, among generic manufacturers)
Drug Class: Short-acting Triazolobenzodiazepine (Benzodiazepine derivative)
Controlled Substance Classification: Schedule IV (US DEA) / Controlled Substance (international regulatory bodies due to potential for abuse and dependence)
Dosage Form: Oral Tablet (Immediate-Release 1 mg, typically blue, elliptical or oval with imprint identifiers like "XANAX 1.0" or generic equivalent codes such as "031 R" or "Y 2.0")
2. Chemical & Physical Properties
Alprazolam contains a triazole ring fused to a 1,4-benzodiazepine ring system, which enhances its binding affinity to specific central nervous system (CNS) receptors.
| |
| 8-chloro-1-methyl-6-phenyl-4$H$-[1,2,4]triazolo[4,3-$a$][1,4]benzodiazepine |
| $\text{C}_{17}\text{H}_{13}\text{ClN}_4$ |
| |
| Insoluble in water; soluble in ethanol and chloroform |
| $228 - 230^\circ\text{C}$ |
3. Mechanism of Action & Pharmacology
Alprazolam acts as a positive allosteric modulator at the GABA-A ($\text{GABA}_\text{A}$) receptor complex in the central nervous system:
GABA Binding Enhancement: It binds to a specific benzodiazepine site located at the interface between the $\alpha$ and $\gamma$ subunits of the $\text{GABA}_\text{A}$ receptor.
Chloride Channel Opening: This binding increases the frequency of chloride channel opening in response to endogenous $\gamma$-aminobutyric acid (GABA), the major inhibitory neurotransmitter.
Hyperpolarization: The influx of chloride ions ($\text{Cl}^-$) leads to neuronal membrane hyperpolarization, dampening neuronal excitability across the limbic system, thalamus, and hypothalamus.
4. Pharmacokinetics (PK) Profile
Understanding the pharmacokinetics of the 1 mg immediate-release formulation is critical for clinical monitoring:
Absorption: Rapidly absorbed following oral administration. Peak plasma concentration ($C_{\text{max}}$) is achieved within 1 to 2 hours post-ingestion.
Distribution: Protein binding is approximately 80% (primarily to human serum albumin). It readily crosses the blood-brain barrier and placenta.
Metabolism: Hepatically metabolized via phase I oxidation by CYP3A4 cytochrome P450 enzymes into two primary active metabolites:
Elimination: Mean plasma elimination half-life ($t_{1/2}$) is approximately 11.2 hours (range: 6.3 to 26.9 hours in healthy adults). Metabolites and unchanged drug are excreted primarily via urine.
5. Clinical Indications & 1 mg Dosage Context
Approved Therapeutic Indications
Clinical Context of the 1 mg Strength
A 1 mg dose is considered a moderate-to-high single dose for immediate-release alprazolam.
Typical starting doses for anxiety are lower ($0.25\text{ mg}$ to $0.5\text{ mg}$ three times daily), while panic disorder treatment often requires titration up to target total daily doses of $3\text{ mg}$ to $6\text{ mg}$ divided throughout the day.
6. Safety, Adverse Effects & Regulatory Concerns
Common Side Effects
Somnolence (drowsiness) and fatigue
Impaired motor coordination and ataxia
Memory impairment (anterograde amnesia)
Cognitive slowdown
Key Clinical Risks
CNS Depression & Black Box Warnings: Concomitant use with opioids or alcohol markedly increases the risk of profound sedation, respiratory depression, coma, and death.
